MECP2 Comprehensive - Sequence & Deletion/Duplication Analysis

Clinical Use

Use

The MECP2 Comprehensive - Sequence & Deletion/Duplication Analysis aims to identify pathogenic variants associated with Rett Syndrome and MECP2 duplication-related syndromes. Rett Syndrome is a neurodevelopmental disorder primarily affecting girls, characterized by normal initial development followed by a regression in skills. Common manifestations include seizures and autistic features. In males, most MECP2 variants lead to severe neonatal conditions. MECP2 duplications involve varying severity, particularly affecting males. This test is indicated for patients suspected of these conditions, being pivotal in guiding management and genetic counseling from early diagnosis.

Special Instructions

Testing is recommended for patients with either a clinical diagnosis or a suspicion of Rett Syndrome or MECP2 duplication. Options for separate MECP2 sequence analysis and deletion/duplication testing are available. For optimal results, samples should be drawn using designated collection methods and prepared following specified guidelines to ensure reliability. Further information can be accessed via our dedicated patient resource platforms and provider references.

Limitations

While the MECP2 analysis effectively detects the majority of pathogenic variants in the gene, there may be rare mutations that are not identified. Additionally, technical limitations might prevent the detection of certain types of deletions or duplications. Results might be influenced by sample quality, and insufficient quantities could render the test inconclusive. External factors, such as successful test execution and laboratory conditions, could also affect results. Genetic counseling is advised for all patients undergoing this testing, as a positive result does not preclude the existence of other health issues.

Test Details